Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients
June 28, 2015 19:01 ET
|
Novartis Pharma AG
In the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained...
Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action
June 26, 2015 07:23 ET
|
Novartis Pharma AG
Farydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD[1] Farydak would be the first HDAC inhibitor with...
Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg
June 18, 2015 17:00 ET
|
Novartis Pharma AG
Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Sandoz has begun shipping to US...
Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
June 18, 2015 01:00 ET
|
Novartis Pharma AG
Strong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and...
Alcon receives European approval for new trifocal presbyopia-correcting intraocular lens for patients undergoing cataract surgery
June 16, 2015 01:15 ET
|
Novartis Pharma AG
Innovative AcrySof® IQ PanOptix® trifocal intraocular lens design to improve near to intermediate vision and increase independence from glasses More than three million cataract surgeries...
Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML
June 13, 2015 09:45 ET
|
Novartis Pharma AG
Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of...
Novartis announces data show majority of patients with polycythemia vera treated with Jakavi® achieved long-term disease control
June 13, 2015 05:45 ET
|
Novartis Pharma AG
Preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year[1] In the study, 83% of patients in the...
Novartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myeloma
June 12, 2015 05:45 ET
|
Novartis Pharma AG
Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an...
Novartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia
June 12, 2015 02:30 ET
|
Novartis Pharma AG
Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus existing...
Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients
June 12, 2015 01:15 ET
|
Novartis Pharma AG
New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2] ...